Receive our newsletter – data, insights and analysis delivered to you
June 14, 2009

Novartis Swine Flu Vaccine Ready for Testing

Novartis has announced that the first batch of its experimental H1N1 (swine flu) vaccine has been produced and is ready for testing. The announcement comes only days after the World Health Organization declared the swine flu outbreak had officially reached pandemic status. Novart

By cms admin

Novartis has announced that the first batch of its experimental H1N1 (swine flu) vaccine has been produced and is ready for testing.

The announcement comes only days after the World Health Organization declared the swine flu outbreak had officially reached pandemic status.

Novartis plans to begin clinical trials of the vaccine in July and licensing towards the end of the year.

The first 10l batch of the vaccine will be used for pre-clinical evaluation and testing, and is also being considered for use in clinical trials.

A Novartis spokesperson said the vaccine had been made in cells rather than grown in eggs and is yet to be tested on humans.

“As well as speed, another advantage of cell-based production is the ability to rapidly increase production, so the facility has the potential to produce millions of doses of vaccine each week,” Novartis said.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

The company’s shares rose 4% following the announcement.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU